Prime Medicine, Inc.

Prime Medicine, Inc. (PRME) priced its initial public offering on Oct 21, 2022 at $17.00 per share, within its $16.00–$18.00 range, raising $175M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.63B. Goodwin Procter advised the company and Davis Polk advised the underwriters.

Prime Medicine, Inc. is a biotechnology company developing one-time curative genetic therapies called Prime Editors, based on its Prime Editing gene editing technology. It aims to address a wide range of diseases caused by diverse genetic mutations.

Status

IPO

Ticker

PRME

Exchange

Nasdaq Global Market

Priced

Oct 21, 2022

IPO price

$17.00

Price range

$16.00–$18.00

Raised

$175M

Market cap at IPO price

$1.63B

First filed

Sep 23, 2022

Company counsel

Goodwin Procter

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.